FTC imposes conditions on AbbVie's acquisition of Allergan
MLex Summary: Pharmaceutical companies AbbVie and Allergan have agreed to divest assets to settle Federal Trade Commission charges that AbbVie’s proposed $63 billion acquisition of Allergan would violate federal antitrust law, the...To view the full article, register now.
Already a subscriber? Click here to view full article